Video
Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial
Author(s):
A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.
A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib (Kyprolis) in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.
The phase III study randomized 792 patients with relapsed multiple myeloma to receive carfilzomib, lenalidomide, and dexamethasone or lenalidomide and dexamethasone alone. The primary endpoint of the study was progression-free survival (PFS).
The study was overwhelmingly positive, Stewart notes. Patients receiving carfilzomib experienced an 8.7-month extension in PFS compared with lenalidomide and dexamethasone alone. The median PFS was 26.3 with carfilzomib versus 17.6 months without (HR = 0.69; 95% CI, 0.57-0.83; P <.0001). At this point, data on overall survival are immature.
<<<
